Ambit Biosciences is combining the power of our KINOMEscan™ kinase profiling technology with an innovative licensing strategy and a history of kinase expertise to discover, optimize and advance a sustainable pipeline of small molecule kinase inhibitors for the treatment of cancer.
Location: United States, California, San Diego
Employees: 51-200
Total raised: $80M
Founded date: 2000
Investors 1
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.11.2012 | - | $50M | - |
| 10.06.2011 | Series D | $30M | - |
Mentions in press and media 11
| Date | Title | Description |
| 06.11.2012 | Ambit Biosciences finds $50M more from VCs as leukemia therapy advances | Venture investors have loosened their purse strings yet again for Ambit Biosciences. The San Diego-based biotech scored $25 million of a $50 million round with the primary purpose of funding development of its lead candidate for treating ac... |
| 06.11.2012 | Ambit Biosciences Completes $50M Round | SAN DIEGO, CA, Privately held biopharmaceutical company has closed the first $25 million tranche of a new $50 million preferred stock financing to support continued advancement of its lead drug candidate, quizartinib. >> Click here... |
| 06.11.2012 | Ambit Biosciences Gets $25M Tranche | San Diego-based Ambit Biosciences announced this morning that it has raised $25M in the first tranche of a $50M preferred stock financing. The round will go towards supporting its lead drug candidate. The round was led by Orbimed Advisors, ... |
| 06.11.2012 | Ambit Biosciences Closes $50M Financing | Ambit Biosciences Inc., a San Diego, CA-based biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications, has closed ... |
| 10.06.2011 | Ambit Biosciences Raises $30M | San Diego-based Ambit Biosciences, which is developing cancer treatments, announced this morning that it has raised $30M in Series D-2 round of funding. The funding was led by Apposite Capital LLP, and also included prior investors Perseus-... |
| 10.06.2011 | Ambit Biosciences Closes $30M Series D-2 Equity Financing | Ambit Biosciences, a San Diego, CA-based biopharmaceutical company that develops kinase inhibitors for the treatment of cancer and other conditions, has completed a $30m Series D-2 equity financing. The round was led by Apposite Capital LLP... |
| 24.07.2009 | Startups Just Want to Have Funds: A Roundup of Recent San Diego Deals | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Venture deals seem to be picking up again in the San Diego region. A number of local startups have been raising capital, according to recent filings with the U.S. Securities a... |
| 29.06.2009 | Ambit Biosciences Gets $6.4M In Debt | San Diego-based Ambit Biosciences, a developer of small molecule profiling tools being used for biopharmaceuticals development, has raised $6.5M in an ongoing, debt round, according to a filing from the firm today. Details on the debt round... |
| 18.01.2008 | VC funding up, biotech outpaces other industries | Venture-capital funding continued to rise in the fourth quarter, continuing a recent boom despite economic jitters sown by the subprime-mortgage financial mess. VCs tossed $7 billion at startups in the fourth quarter, a substantial 12 perce... |
| 14.11.2007 | Life sciences briefing: Wednesday, Nov. 14, 2007 | Featured companies: Advanced Bio-Surfaces, Ambit Biosciences, EnteroMedics, Molecular Vision, Skyline Ventures UPDATED: Expanded items on Skyline Ventures, Ambit, and Molecular Vision, and moved EnteroMedics to a new item here. Skyline Vent... |
Show more